Is there any upside left for lxrx stock

**Lexicon Pharmaceuticals (LXRX) has significant upside potential based on analyst ratings and price targets.** Here's the analysis to support this conclusion:

1. **Analyst Ratings and Price Targets**:
- LXRX has a strong buy consensus rating from analysts, with no hold or sell ratings in the past 3 months.
- The average price target is $8.33, with a high estimate of $10.00 and a low estimate of $5.00.
- This represents a 370.62% upside from the last price of $1.77.
2. **Recent Positive Developments**:
- The FDA has accepted Lexicon's resubmitted NDA for Zynquista, which could lead to potential approval and market expansion.
- The company has also announced strategic cost savings initiatives that could improve operational efficiency.
3. **Technical Indicators**:
- The MACD is at 0.03, which could indicate a potential bullish trend.
- The RSI is at 50.48, suggesting the stock is neither overbought nor oversold.
- The stock is currently trading below its 5-day, 10-day, and 50-day moving averages, but these are all relatively close to the current price, indicating a tight range and potential for price movement.
4. **Support and Resistance Levels**:
- The narrow support level is at $1.75, and the resistance level is at $1.8. The stock is currently trading close to the support level, which could be a point of interest for potential buyers.
5. **Market Sentiment**:
- Despite a recent drop in stock price, there is a positive sentiment among analysts, with an average price target that suggests a significant upside.
- The company's strategic initiatives and potential FDA approval could contribute to positive market sentiment.

In conclusion, Lexicon Pharmaceuticals (LXRX) has a strong buy consensus from analysts, with an average price target that indicates a substantial upside from the current price. The company's recent positive developments, technical indicators, and market sentiment all support the view that LXRX has significant growth potential.